A Goldilocks Approach: FDA Launches New Fit-for-Purpose Framework for Rare Disease Drug Development

Key Takeaways

• FDA is pursuing more flexible rare disease drug reviews. The new framework aims to align evidentiary requirements with small patient populations and disease-specific challenges.
• Drug developers could gain greater regulatory predictability. More consistent FDA review standards may reduce development uncertainty, inform clinical trial strategies, and support investment decisions.

Similar to Goldilocks searching for porridge that is neither too hot nor too cold in the classic 19^th-century fairytale, Goldilocks and the Three Bears, the Food and Drug Administration is looking for an approach to rare disease drug development that is just right. The agency recently launched the Rare Disease Framework Initiative to create a fit-for-purpose process for developing and reviewing rare disease drugs and biologics, recognizing the unique challenges associated with small patient populations.¹

FDA Rare Disease Framework Initiative: Key Goals and Proposed Changes

• FDA says its decision making will be tailored to what evidence is reasonably attainable given the nature of the disease, its onset and progression, the target population, patient needs, and the particular product. The Initiative covers the full product lifecycle, from pre-Investigational New Drug applications through post-approval obligations and chemistry, manufacturing, and controls (“CMC”) requirements.
• FDA has committed to improvement in six core areas:

• 1. greater clarity, consistency, and predictability in decision making;
  2. including the patient voice early and at defined points;
  3. drawing on more outside expertise;
  4. building shared resources, reviewer training, and institutional knowledge on rare disease development;
  5. applying risk-based approaches to CMC review and pre-approval inspections; and
  6. promoting cutting-edge science and new statistical approaches.

• The agency plans to revise existing regulations and create new regulatory provisions that embed fit-for-purpose evidentiary standards into the rare disease review process. FDA also expects to review and revise guidance on endpoints, statistical approaches, trial design, patient engagement, and post-approval obligations, and to align practices between the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.

What FDA’s Rare Disease Framework Means for Drug Developers

• Approximately 30 million Americans live with a rare disease, yet only about 5% of recognized rare diseases have an FDA-approved treatment. Rare disease populations are often small and geographically dispersed, natural history data is frequently sparse, and validated biomarkers may not exist.² As a result, standard tools, such as placebo-controlled trials, may not be available.
• FDA acknowledges that it has often tailored its review of orphan drugs, but it now wants every review division to take that approach as a matter of course. To get there, the agency plans to unify its many separate rare disease programs into a single, consistent, cross-center approach. Recent high-profile FDA reversals on the use of external controls in treatment development, such as for Huntington’s disease, show how costly inconsistent review can be for sponsors.³
• A framework that recognizes and builds around rare disease constraints could encourage investment in conditions that previously seemed too small or too uncertain to pursue. It could also help bring safe and effective therapies to patients living with the approximately 95% of rare diseases that lack approved treatment.

Key Regulatory Considerations for Rare Disease Drug Sponsors

• Predictability should improve. The Initiative builds on the plausible mechanism pathway announced last year for individualized therapies for very small populations.⁴ It goes further by aiming to standardize how evidentiary flexibility is applied across divisions rather than relying on case-by-case accommodations.
• The details will matter. Much will depend on forthcoming guidance and rulemaking. The Alliance for Regenerative Medicine noted, for example, that success in cell and gene therapy will turn on how FDA treats single-arm trials and natural history data.⁵ While it may take a while to see a change in review standards as the agency gathers feedback, the Initiative signals a positive regulatory direction.
• Industry can get involved. FDA plans to publish a request for information in the Federal Register and to host roundtables with specific industry sectors, providing meaningful opportunities to help shape a framework that is just right.

AGG will continue to track the Initiative as it develops. For guidance on these issues, please contact a member of AGG’s Food & Drug team.

[1] Press Release, U.S. Food & Drug Admin., “FDA Launches the Rare Disease Framework Initiative to develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development,” October 14, 2026. See also U.S. Food & Drug Admin., “A New Framework for Rare Disease Review 5,” October 2026, noting that a 2024 GAO report identified 18 FDA rare disease programs, most launched since 2019, and listing current efforts such as the Rare Disease Innovation Hub, CDER’s Accelerating Rare disease Cures (“ARC”) program, the Support for clinical Trials Advancing Rare disease Therapeutics (“START”) pilot program, and the Rare Disease Endpoint Advancement (“RDEA”) pilot program.

[2] Natural history data comes from an observational study that tracks how a disease progresses over time in patients without experimental treatment.

[3] External controls compare trial participants against patients outside the study, often using natural history data, instead of a concurrent placebo group. In November 2025, FDA reversed its earlier guidance and disagreed that an early-stage study of a Huntington’s disease gene therapy, which relied on a natural history external control, could support a marketing application. See, e.g., Marco Meglio, “FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission,” NeurologyLive, November 27, 2025.

[4] The plausible mechanism pathway is intended for individualized therapies for conditions so rare that a randomized controlled trial is not feasible. FDA requires sponsors to meet five criteria and demonstrate success in consecutive patients with different bespoke therapies. Sponsors then proceed through the traditional or accelerated approval pathway.

[5] Press Release, All for Regenerative Med., “ARM Statement of FDA Rare Disease Framework,” October 14, 2026.